PREVACID (lansoprazole) by Takeda is proton pump inhibitors [moa]. First approved in 1995.
Drug data last refreshed 2d ago
PREVACID (lansoprazole) is an oral proton pump inhibitor (PPI) approved by the FDA in May 1995 for treating acid-related gastrointestinal conditions. It works by irreversibly inhibiting gastric H+/K+-ATPase, suppressing gastric acid secretion and providing relief from conditions like GERD, peptic ulcer disease, and acid reflux. As a delayed-release capsule formulation, PREVACID represents a foundational PPI therapy that has been a cornerstone of acid-suppression treatment for nearly three decades.
Proton Pump Inhibitors
Proton Pump Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Worked on PREVACID at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPREVACID's mature lifecycle and generic erosion create limited career opportunities compared to growth-stage products; roles are primarily defensive in nature including brand management, managed care support, and medical affairs focused on maintaining market share against generics. Professionals supporting this product require expertise in formulary management, healthcare economics, and generic competition strategies rather than clinical development or field promotion. Approximately 1,291 open roles are currently linked to PREVACID, likely reflecting broader PPI market positions across multiple organizations rather than dedicated brand-specific opportunities.